Graham, M A <br/><br/>
Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.  [electronic resource] 

 -  Cancer research  Feb 1992 
 - 603-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0008-5472 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anthraquinones--pharmacokinetics<br/>Antineoplastic Agents--pharmacokinetics<br/>Blood Proteins--metabolism<br/>Carbon Radioisotopes<br/>Drug Evaluation<br/>Glomerular Filtration Rate--drug effects<br/>Humans<br/>Metabolic Clearance Rate<br/>Neoplasms--drug therapy<br/>Orosomucoid--metabolism<br/>Protein Binding<br/>Pyrazoles--pharmacokinetics<br/>Pyrazolones<br/>Regression Analysis<br/>Tissue Distribution